Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma

Hepatology

Volumn 52, Issue 6, 2010, Pages 1922-1933

  Yeh, Chau Ting ^a,c   So, Mary ^d   Ng, Jennifer ^d   Yang, Han Wen ^a   Chang, Ming Ling ^a   Lai, Ming Wei ^e   Chen, Tse Ching ^b   Lin, Chun Yen ^a   Yeh, Ta Sen ^b   Lee, Wei Chen ^b  

^a Liver Research Unit   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CANCER SURVIVAL; CODON; DELETION MUTANT; DISEASE FREE SURVIVAL; FEMALE; GENE DELETION; GENE MUTATION; GENOTYPE; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CODON, TERMINATOR; DNA, VIRAL; FEMALE; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROMOTER REGIONS, GENETIC;

EID: 78649597541     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23898     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538.
3. Tanaka K, Hirohata T, Takeshita S, Hirohata I, Koga S, Sugimachi K, et al. Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: a case-control study in Fukuoka, Japan. Int J Cancer 1992; 51: 509-514.
4. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 191-211.
5. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127(5 Suppl. 1): S27-S34.
6. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005; 25: 143-154.
7. Kensler TW, Egner PA, Wang JB, Zhu YR, Zhang BC, Lu PX, et al. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology 2004; 127(5 Suppl. 1): S310-S318.
8. Yuen MF, Tanaka Y, Shinkai N, Poon RT, But DY, Fong DY, et al. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut 2008; 57: 98-102.
9. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 1134-1143.
10. Huang Y, Wang Z, An S, Zhou B, Zhou Y, Chan HL, et al. Role of hepatitis B virus genotypes and quantitative HBV DNA in metastasis and recurrence of hepatocellular carcinoma. J Med Virol 2008; 80: 591-597.
11. Chen JD, Liu CJ, Lee PH, Chen PJ, Lai MY, Kao JH, et al. Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2004; 2: 64-71.
12. Sun HC, Zhang W, Qin LX, Zhang BH, Ye QH, Wang L, et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol 2007; 47: 684-690.
13. Park NH, Song IH, Chung YH. Chronic hepatitis B in hepatocarcinogenesis. Postgrad Med J 2006; 82: 507-515.
14. Shen HM, Ong CN. Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat Res 1996; 366: 23-44.
15. Hsu YC, Fu HH, Jeng YM, Lee PH, Yang SD. Proline-directed protein kinase FA is a powerful and independent prognostic predictor for progression and patient survival of hepatocellular carcinoma. J Clin Oncol 2006; 24: 3780-3788.
16. Tsujita E, Taketomi A, Gion T, Kuroda Y, Endo K, Watanabe A, et al. Suppressed MKP-1 is an independent predictor of outcome in patients with hepatocellular carcinoma. Oncology 2005; 69: 342-347.
17. Kobayashi T, Kubota K, Takayama T, Makuuchi M. Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy. Am J Surg 2001; 181: 284-288.
18. Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, Lo CM, et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 2001; 233: 227-235.
19. Kitamoto M, Nakanishi T, Kira S, Kawaguchi M, Nakashio R, Suemori S, et al. The assessment of proliferating cell nuclear antigen immunohistochemical staining in small hepatocellular carcinoma and its relationship to histologic characteristics and prognosis. Cancer 1993; 72: 1859-1865.
20. Poon RT, Lau CP, Ho JW, Yu WC, Fan ST, Wong J. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 2003; 9: 5339-5345.
21. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003; 94: 851-857.
22. Chau GY, Wu CW, Lui WY, Chang TJ, Kao HL, Wu LH, et al. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 2000; 231: 552-558.
23. Feitelson MA. Hepatitis B virus in hepatocarcinogenesis. J Cell Physiol 1999; 181: 188-202.
24. Hsu CW, Yeh CT, Chang ML, Liaw YF. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology 2007; 132: 543-550.
25. Yeh CT, Hsu CW, Chen YC, Liaw YF. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. J Clin Virol 2009; 45: 114-118.
26. Yeh CT, Kuo CJ, Lai MW, Chen TC, Lin CY, Yeh TS, et al. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. BMC Cancer 2009; 9: 324.
27. Chou YC, Yu MW, Wu CF, Yang SY, Lin CL, Liu CJ, et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut 2008; 57: 91-97.
28. Yang JC, Teng CF, Wu HC, Tsai HW, Chuang HC, Tsai TF, et al. Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. HEPATOLOGY 2009; 49: 1962-1971.
29. Abe K, Thung SN, Wu HC, Tran TT, Le Hoang P, Truong KD, et al. Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. Cancer Sci 2009; 100: 2249-2254.
30. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554-559.
31. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124: 327-334.
32. Dong Q, Chan HL, Liu Z, Chan DP, Zhang B, Chen Y, et al. A1762T/G1764A mutations of hepatitis B virus, associated with the increased risk of hepatocellular carcinoma, reduce basal core promoter activities. Biochem Biophys Res Commun 2008; 374: 773-776.
33. Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst 2009; 101: 1066-1082.
34. Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 2006; 130: 1153-1168.
35. Chen CH, Hung CH, Lee CM, Hu TH, Wang JH, Wang JC, et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 2007; 133: 1466-1474.